PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 5,366,726 units. Each unit consists of one common share (or one pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warran ...

Group 1 - U.S. stock futures are lower, with Dow futures down approximately 100 points [1] - Glaukos Corp reported preliminary FY25 sales of $507 million, leading to a 12.1% drop in shares to $96.97 in pre-market trading [1] Group 2 - Briacell Therapeutics Corp experienced a significant decline of 53.1% to $5.12 after announcing a $30 million public offering [2] - Trip.com Group Ltd shares fell 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [2] - Pearson PLC shares decreased by 7.2% to $13.36 following a trading update for 2025 [2] - Olema Pharmaceuticals Inc shares declined 5.5% to $26.37 after a previous drop of 3% [2] - Fresenius Medical Care AG shares fell 4.8% to $21.79 [2] - Ambitions Enterprise Management Co LLC shares dropped 4.3% to $11.81 after a significant increase of 134% the previous day [2] - NovaBay Pharmaceuticals Inc shares decreased by 3.8% to $12.55 following a 3% drop on Tuesday [2] - SmartRent Inc shares fell 2.3% to $1.74 in pre-market trading [2]

Group 1 - BriaCell Therapeutics Corp. announced a public offering of 5.367 million units priced at $5.59 per unit, aiming for gross proceeds of approximately $30 million [1] - Each unit consists of one common share and one warrant, with the warrant exercisable at $6.93 per share and expiring five years from issuance [1] - Following the announcement, the stock price dropped 54.12% to $5.01 [2] Group 2 - The warrants have been approved for listing on the Nasdaq Capital Market under the symbol "BCTXL," expected to begin trading on January 14, 2026 [2] - The offering is anticipated to close on January 15, 2026 [2] - The company plans to use the net proceeds for working capital and general corporate purposes [3] Group 3 - BriaCell recently reported a sustained complete resolution of lung metastasis in a breast cancer patient treated with its Bria-OTS personalized immunotherapy, boosting stock prices to $12.10 [3] - Over 11 months, the treatment response was confirmed without treatment-limiting toxicities, enhancing confidence in the Bria-OTS platform [4] - The stock traded between $3.00 and $98.20 over the past year, closing at $10.92, up 43.12% prior to the offering announcement [4]

Group 1: Company Performance - Gelteq Ltd (NASDAQ:GELS) shares rose sharply by 50.1% to $1.25 in pre-market trading after reporting positive preclinical results for its cannabinoid oral gel delivery platform [1][2] - The proprietary oral gel platform achieved a greater than 22% increase in the bioavailability of cannabidiol compared to an existing FDA-approved oil-based product [1] Group 2: Other Notable Stock Movements - Inspire Veterinary Partners Inc (NASDAQ:IVP) gained 141.3% to $0.056 after filing a Certificate of Amendment to increase its authorized Class A common stock from 100 million to 700 million shares [5] - Oriental Culture Holding Ltd (NASDAQ:OCG) rose 40.8% to $0.016 following the board's approval of a special cash dividend of 5 cents per share [5] - XCF Global Inc (NASDAQ:SAFX) gained 30.2% to $0.22 after announcing expansion financing plans [5] - AiRWA Inc (NASDAQ:YYAI) rose 15.8% to $1.46 after a director purchased 1.109 million shares at an average price of $1.35 per share [5] - Autolus Therapeutics PLC (NASDAQ:AUTL) gained 7.3% to $1.47 after announcing preliminary fourth-quarter and FY25 revenue results [5] Group 3: Declining Stocks - Briacell Therapeutics Corp (NASDAQ:BCTX) fell 53.1% to $5.12 after announcing the pricing of a $30 million public offering [5] - Moolec Science SA (NASDAQ:MLEC) fell 19.8% to $3.94 after a previous jump of 19% [5] - Hub Cyber Security Ltd (NASDAQ:HUBC) fell 19.1% to $0.43 after gaining 56% on the previous day [5] - Trip.com Group Ltd (NASDAQ:TCOM) dipped 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [5]

Core Viewpoint - BriaCell Therapeutics Corp. has announced a public offering of 5,366,726 units at a price of $5.59 per unit, aiming to raise approximately $30 million before expenses [1][2]. Group 1: Offering Details - Each unit consists of one common share (or a pre-funded warrant) and one warrant, with the warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXL" [1]. - The warrants are immediately exercisable at an exercise price of $6.93 per share and will expire five years from issuance [1]. - The offering is expected to close on January 15, 2026, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund working capital requirements, general corporate purposes, and to advance the company's business objectives [3]. Group 3: Regulatory Information - A registration statement related to the securities was filed with the SEC on December 23, 2025, and became effective on January 13, 2026 [4]. - The offering is being made only by means of a prospectus, with copies available from ThinkEquity and on the SEC's website [4]. Group 4: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [6].

Core Viewpoint - BriaCell Therapeutics Corp. has announced a public offering of 5,366,726 units at a price of $5.59 per unit, aiming to raise approximately $30 million before expenses [1][2]. Group 1: Offering Details - Each unit consists of one common share (or a pre-funded warrant) and one warrant, with the warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXL" [1]. - The warrants are immediately exercisable at an exercise price of $6.93 per share and will expire five years from issuance [1]. - The offering is expected to close on January 15, 2026, subject to customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for working capital requirements, general corporate purposes, and advancing the company's business objectives [3]. Group 3: Regulatory Information - A registration statement related to the securities was filed with the SEC on December 23, 2025, and became effective on January 13, 2026 [4]. - The offering is being made only by means of a prospectus, with copies available from ThinkEquity [4]. Group 4: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [6].

Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading, driven by corporate updates, clinical milestones, and acquisition speculation [1] Company Updates - China SXT Pharmaceuticals, Inc. (SXTC) saw a 13.6% increase to $1.42, following the announcement of its Strategic Artificial Intelligence Insights Initiative aimed at integrating AI-driven analytics into product planning and market intelligence [2] - Revolution Medicines, Inc. (RVMD) surged 15.1% to $123.65 after reports of Merck's acquisition talks and the FDA granting Breakthrough Therapy Designation to its drug zoldonrasib for treating specific lung cancer patients [3] - KalVista Pharmaceuticals, Inc. (KALV) advanced 14.0% to $18.04 after reporting preliminary unaudited global net product revenue results for Q4 and the full year ended December 31, 2025, along with other operational indicators [4] - Zentalis Pharmaceuticals, Inc. (ZNTL) rose 8.1% to $3.07, likely due to investor reactions to a previous corporate update outlining key milestones for its drug azenosertib [5] - BriaCell Therapeutics Corp. (BCTX) gained 7.3% to $7.81 without new announcements, indicating momentum-driven trading [6] - Sagimet Biosciences Inc. (SGMT) increased 7.7% to $6.00 after announcing plans to present clinical trial results at an upcoming conference, highlighting anti-fibrotic effects observed in patients [7]

BRIACELL THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) British Columbia 2834 47-1099599 As filed with the U.S. Securities and Exchange Commission on December 23, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (State or other jurisdiction of incorporation or organization) (Primary standard industrial classification code number) (I.R.S. employer identification numbe ...

Core Insights - BriaCell Therapeutics Corp.'s Phase 3 Bria-IMT™ clinical trial in metastatic breast cancer has been highlighted in Nature Medicine's Year In Review as a significant trial to watch in 2026 [1][8] Group 1: Clinical Trial Details - The BRIA-ABC trial aims to evaluate the effectiveness of Bria-IMT, a new cell-based immunotherapy, in improving outcomes for patients with metastatic breast cancer who have undergone multiple prior treatments [2][3] - The trial is inclusive, allowing participation from individuals with all breast cancer subtypes, including those with brain metastases and extensive prior treatments [2] - BriaCell has screened over 230 patients and enrolled more than 160 patients to date, with interim data analysis planned once 144 patient events occur [4] Group 2: Regulatory and Market Implications - Positive results from the Phase 3 study could lead to full approval and marketing authorization of Bria-IMT for metastatic breast cancer patients [4] - The Bria-IMT combination regimen has received FDA Fast Track designation, which may expedite its development and review process [4]

Clinical Trials and Research - BriaCell reported a median overall survival of 13.4 months for metastatic breast cancer patients treated with Bria-IMT™, compared to 6.7-9.8 months for similar patients in literature[72]. - Research and development expenses rose to $6,683,643 for the three months ended October 31, 2025, up from $3,665,341 in 2024, primarily due to increased clinical trial costs[86]. - Clinical trial expenses for the pivotal Phase 3 study of Bria-IMT™ were $3,792,951 for the three months ended October 31, 2025, compared to $2,446,461 in 2024[87]. - The company is advancing its pivotal Phase 3 clinical study of Bria-IMT™ with 79 clinical sites across 23 U.S. states enrolling patients, with top-line data expected in the first half of 2026[79]. - The independent Data Safety Monitoring Board recommended the continuation of the Phase 3 trial without modification, indicating no safety concerns[79]. - BriaCell's Bria-OTS™ personalized immunotherapy platform is under development, with positive feedback received from the FDA for Bria-PROS+™ for prostate cancer[73]. - Bria-OTS™ Phase 1/2a expenses rose significantly to $988,038 compared to $77,588 in 2024, driven by expanded preclinical development and increased patient enrollment[90]. - BriaCell's collaboration with Receptor.AI aims to expand its small-molecule oncology pipeline using AI to design selective anti-cancer kinase inhibitors[82]. Financial Performance - Total operating expenses for the three months ended October 31, 2025, were $8,322,943, an increase from $5,152,832 in the same period of 2024[84]. - General and administrative expenses for the same period were $1,639,300, up from $1,487,491 in 2024, primarily due to higher shareholder communication costs and increased wages[92]. - The company reported a net loss of $8,278,328 for the three-month period ended October 31, 2025, compared to a loss of $5,829,276 in 2024, attributed to increased R&D spending[94]. - Financial income for the period was $158,646, significantly higher than $11,714 in 2024, due to increased interest income and unrealized gains on short-term investments[93]. - As of October 31, 2025, the company had total assets of $13,075,050, down from $21,649,706 on July 31, 2025, with a positive working capital balance of $8,030,634[96]. - The company experienced a decrease in cash and cash equivalents by $7,779,796 from July 31, 2025, with net cash used in operating activities amounting to $7,704,796[99]. - The company intends to raise additional capital through debt or equity financing to support its business plan objectives, although there are risks associated with this[98]. Grants and Funding - BriaCell received a $2.0 million SBIR grant from the U.S. National Cancer Institute to support the Bria-PROS+™ program in prostate cancer[78]. Shareholder and Compliance - The company announced a share consolidation of one post-consolidation common share for every ten pre-consolidation shares to comply with Nasdaq listing requirements[76]. - The company has no off-balance sheet arrangements or new accounting policies adopted during the period[101][104]. Risk Factors - The company is exposed to foreign exchange risk, particularly with transactions in Canadian Dollars, but a 5% fluctuation would not materially affect the total loss[112].